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Abstract
Introduction: Hypertension is an important risk factor for cardiovascular disease and its management requires improvement. 
New treatment strategies are needed. 
Aims: This review analyses one of these strategies, which is the development of effective and safe combination therapy. Indeed, at least 
two antihypertensive agents are often needed to achieve blood pressure control. Exforge® (Novartis) is a new drug combination of the 
calcium channel blocker, amlodipine, and the angiotensin II receptor blocker, valsartan. 
Evidence review: The amlodipine/valsartan combination is an association of two well-known antihypertensive products with specific 
targets in cardiovascular protection, namely calcium channel blockade and antagonism of the renin-angiotensin-aldosterone system. This 
kind of association, with neutral metabolic properties and significant antihypertensive efficacy, could be a useful new antihypertensive 
product. Currently available data have shown that this new combination is well-tolerated and effective even in severe hypertension.  
Clinical value: Clinical trials are ongoing for further assessment of the efficacy, compliance, and safety of this combination and its 
congeners. No data exist to prove that the amlodipine/valsartan combination is better than other antihypertensive strategies for 
cardiovascular or renal protection, but some trials with other combination therapies show such potential advantage.
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Core evidence clinical impact summary for Exforge (amlodipine/valsartan) in hypertension
Outcome measure Evidence Implications
Patient-oriented evidence
Improvement in cardiovascular morbidity and mortality Clear (for each 
agent alone)
Trials on both drugs as monotherapy have shown either direct 
protection against cardiovascular events or surrogate benefit 
by reducing blood pressure
Reduced atrial fibrillation Moderate Reduced recurrent atrial fibrillation 
Patient acceptability Limited Low rate of adverse events
Improvement in quality of life Moderate Less edema, better tolerability
Disease-oriented evidence
Effective control of blood pressure Clear Combination more effective than monotherapy 
Economic evidence
Cost effectiveness as antihypertensive therapy Limited No studies to show the long term efficacy for lowering blood 
pressure and decreasing morbidity or mortality in spite of 
higher cost of the fixed combination 
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Scope, aims, and objectives
This article discusses the place of combination therapy in arterial 
hypertension (HTN) and concentrates on the potential advantage 
of Exforge® (Novartis), the first commercially available combination 
of a dihydropyridine calcium channel blocker (CCB) (amlodipine) 
and an angiotensin II receptor blocker (ARB) (valsartan). These 
are two of the most commonly prescribed antihypertensive drugs 
in their classes. Their combination aims to secure better control 
of blood pressure (BP) along with simultaneous cardiovascular 
and renal risk reduction and few side effects. The scope of this 
article is in the area of human hypertension and its treatment, with 
particular focus on amlodipine, valsartan, and their combination.
Methods
An extensive literature search on amlodipine/valsartan was 
conducted as follows.
Peer reviewed articles and abstracts (English-language only) 
were identified from Medline, EMBASE, BIOSIS, the National 
Institute for Health and Clinical Excellence (NICE), and the York 
University Centre for Reviews and Dissemination Database 
(http://www.crd.york.ac.uk/crdweb/) using the terms “antihypertensive 
combination, amlodipine, valsartan, CCB, and ARB”.
PubMed was used for the terms “amlodipine and valsartan” with 
the search limits “clinical trial, meta-analysis, practice guideline, 
randomized controlled trial, hypertension treatment”, and English 
language only. Forty-nine records were found, of which 11 were 
reviews on the topic. Only 15 of the records appeared relevant 
to the combination of both drugs. The search also produced 
records of trials that compared amlodipine and valsartan; they 
were included in this review to substantiate the evidence of the 
efficacy and tolerability of each individual drug.
A search on the site of the European Medicines Agency (EMEA), 
(www.emea.europa.eu), was also done with Exforge as the 
topic searched. EMBASE and BIOSIS were also consulted with 
the same search keywords, but the records that were identified 
were already found in the PubMed results. For NICE, no records 
were found. From the York University Centre for Reviews and 
Dissemination Databases, four records were identified, but for the 
purpose of the present article, none were judged relevant. The 
results of the literature search are shown in Table 1.
The main aims of all the studies selected were the efficacy of 
antihypertensive effect and tolerability.
Most of these articles were the results of prospective, randomized, 
either double-blind or open-label multicenter studies, placebo- 
or active-treatment controlled, with samples including men and 
women of a mean age around 60 years. Additional references 
were obtained from the authors’ files.
Disease overview
Hypertension is a well-known risk factor for cardiovascular 
disease, affecting more than 1 billion people worldwide. Recently, 
Lawes et al. (2008) summarized the worldwide burden of disease 
attributable to high BP and found that 7.6 million premature 
deaths and 92 million disability-adjusted life years were attributed 
to high BP. Half of strokes and ischemic heart disease worldwide 
were attributable to high BP. About half this burden was in people 
with HTN, the remainder was in those with lesser degrees of high 
BP. The prevalence of HTN varies according to the country, with 
a range between 5% in rural India to 70% in Poland (Kearney et 
al. 2004).
The economic impact of HTN is enormous, representing 
$US24 billion in the US in 1995, and more than one-third of that 
cost is due to drug treatment (Pardell et al. 2000). Further, Goetzel 
et al. (2004) suggest that HTN carries a high per-employee cost, 
even higher than that of heart disease, depression, or arthritis.
Despite the effort to increase the awareness and treatment of 
HTN, recent data for the US show that only 39% of patients have 
their BP adequately controlled (Ma & Stafford 2008). In Europe, BP 
control was achieved in only 12% of Polish hypertensives and up 
to 36% of Spanish hypertensives (Erdine 2007). These statistics 
show the need to change the landscape of BP management.
Current therapy options
The Seventh Report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of HTN (Chobanian et al. 
2003) recommends a BP treatment goal of <140/90 mmHg for 
most patients and <130/80 mmHg for those with diabetes mellitus 
or chronic kidney disease. These targets conform to the more 
recent European guidelines (Mancia et al. 2007). These target BP 
goals should reduce the long-term risk of cardiovascular disease 
and death. In most hypertensive subjects, optimal control of the 
BP will depend on effective and trouble-free medication.
Choosing the appropriate medications for individual patients and 
adherence to these regimens are the key factors for successful 
treatment of HTN. Diuretics remain an important drug class 
with a large amount of evidence for their efficacy. They are also 
   Table 1 |  Evidence base included in the review
Category Number of records
Full papers Abstracts
Initial search
records excluded
records included
Additional studies identified
Total records included
Level 1 clinical evidence  
(systematic review, meta analysis)
Level 2 clinical evidence (RCT)
Level ≥3 clinical evidence 
trials other than RCT
Economic evidence
49
34
15
46
61
10
37
11
3
12
1
1
2
For definitions of levels of evidence, see inside back cover or Core Evidence website 
(http://www.coremedicalpublishing.com).
RCT, randomized controlled trial.
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inexpensive, but they have potential adverse metabolic side 
effects. When used alone, they are often stopped during the first 
year of their use, with a one-year persistence rate of only 34% 
(Hasford et al. 2002). 
Medications that act on the renin-angiotensin-aldosterone 
system (RAAS) are now frequently prescribed because they 
block important renal mechanisms that play a crucial role in salt 
and volume homeostasis, and because of additional extrarenal 
actions. They also reduce major cardiovascular events in high-
risk patients (Yusuf et al. 2000, 2008).
For their part, calcium antagonists have regained popularity in 
spite of worries about short-acting calcium antagonists (Alderman 
et al. 1997). They have been used in many recent hypertension 
treatment trials (e.g. ALLHAT, VALUE, ASCOT) and may have 
utility because of their neutral metabolic effects and also potential 
antiatherosclerotic properties. 
The current market share in the US for angiotensin-converting 
enzyme (ACE) inhibitors and angiotensin-receptor blockers 
(ARBs) is near 50%, while that of calcium blockers is 20% 
(Stafford et al. 2006). These are thus major drug classes for the 
treatment of hypertension. 
Unmet needs
Of the unmet medical needs in the management of HTN, there 
is strong evidence to support simpler treatment regimens that 
effectively control BP and that are still used by patients in the 
long term because they are well tolerated. 
Major trials, such as LIFE, ASCOT, and VALUE, have shown 
that up to 80% of hypertensive patients need more than one 
antihypertensive agent to get to and maintain their BP goal. In 
the Hypertension Optimal Treatment study (HOT), an average of 
3.3 drugs were required to attain a diastolic BP goal of <80 mmHg 
(Hansson et al. 1998). Furthermore, the JNC7 recommendations 
state that “when BP is more than 20 mmHg above systolic goal or 
above 10 mmHg diastolic goal, consideration should be given to 
initiate with 2 drugs, either as separate prescriptions or in fixed-
dose combinations” (Chobanian 2003).
For those with reduced kidney function, the number of 
medications needed to control BP rises as the glomerular filtration 
rate (GFR) falls (K/DOQI clinical practice guidelines 2004) (Fig. 1). 
Combination therapy thus appears to be an attractive option for 
the 10% of hypertensives who have stage II hypertension or more 
and for those with chronic kidney disease and HTN.
Combination therapy could improve adherence to therapy 
(“compliance”), due to reduction of the daily pill intake (Osterberg 
& Blaschke 2005). Better adherence to HTN therapy could 
enhance individual and population-level BP control. Some authors 
consider that improvement of treatment compliance could yield 
the greatest gain both in cost effectiveness and efficiency (Mar & 
Rodriguez-Artalejo 2001).
In addition, BP has multiple regulatory pathways, including the 
sympathetic nervous system, RAAS, and total body sodium. 
Combination therapy relies on efficient and complementary 
blockade of more than one of these, by separate and different 
agents, and without resorting to a high dose of either. This was 
shown by Andreadis et al. (2005) who noted that low-dose 
ARBs and CCBs had comparable effects in patients with grade 
I and II HTN. In patients who were not controlled by low-dose 
monotherapy, low-dose combination therapy using agents 
blocking different BP control pathways was more effective than 
was high-dose monotherapy. Such a complementary advantage 
was also reported by Stergiou et al. (2005) who showed that 
adding amlodipine or chlorthalidone to valsartan was more 
effective than add-on therapy with benazepril. 
Additional reasons for inadequate BP control could derive from 
a suboptimal approach by physicians (Berlowitz et al. 1998). Yet 
the role of BP reduction in cardiovascular risk prevention is quite 
clear, and a greater reduction in BP yields greater reduction in 
risk (Staessen et al. 2005; LeLorier 2006). Getting to goal BP may 
require more than one antihypertensive drug.
Over the years, several combinations with fixed-dose drugs 
have been developed and shown to be effective. Some have 
had specific indications based on hemodynamic and metabolic 
criteria (van Zwieten 2003). These have included:
1.  Thiazide diuretics and either beta blocker, ACE inhibitor, or 
ARB, for uncomplicated HTN, for heart failure, or left ventricular 
hypertrophy, respectively. 
2.  CCB and betablocker for HTN and coronary artery disease, 
or CCB and ACE inhibitor for HTN with kidney disease or with 
high cardiovascular risk. 
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Fig. 1 | Relationship between level of baseline GFR and number 
of antihypertensive medications needed to achieve BP goal. 
SBP reflects BP ranges in the studies reviewed.  
Adapted from studies reviewed in 2004 Disease Outcomes 
Quality Initiative–Blood Pressure (DOQI -BP) guidelines.  
Black squares are diabetic studies; black diamonds are 
nondiabetic studies. This figure is reprinted by permission of 
the American Society of Nephrology and by Dr George Bakris, 
from NephSAP 4:101, 2005, the Nephrology Self-Assessment 
Program published by the American Society of Nephrology.  
BP, blood pressure; GFR glomerular filtration rate; SBP,  
systolic BP.
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The side effects of diuretics, beta blockers, and ACE inhibitors 
may limit the benefit of combinations using these drugs and also 
decrease patient adherence to treatment.
The combination of amlodipine/valsartan has been developed 
to try to improve efficacy and tolerability and thus deliver 
the promise of better treatment. Both amlodipine and valsartan 
have a favorable side effect profile, so their combination is 
attractive. Both drugs act on different mechanisms of hypertension 
and thus could be complementary in the benefit that they offer.
Pharmacodynamic profile 
The CCB is effective in low-renin HTN and the ARB in 
high-renin HTN, thus combining both classes could improve 
the success of treatment. Both drugs have generally neutral 
effects on metabolic parameters such as blood lipid levels and 
insulin sensitivity, although plasma norepinephrine levels are 
increased with amlodipine therapy. This effect is not attenuated 
when combined therapy is used (de Champlain 2007). 
Amlodipine
Amlodipine is a third generation CCB that acts on specific 
high-affinity binding sites in the L-type calcium channel complex 
of vascular smooth muscle cells. This causes vasodilatation 
of arteries and arterioles by reducing the influx of calcium into 
vascular smooth muscle. Calcium channels play important roles 
in cardiac contractility and electrophysiology but much higher 
concentrations of amlodipine are needed in vitro to influence those 
functions (Burges et al. 1987). Its protein binding and elimination 
kinetics help to explain its long duration of action. Amlodipine 
produces a gradual onset of action and a prolonged effect that 
enables once-daily dosing. This explains the high trough-to-peak 
ratio of the antihypertensive effect and reduced variability of BP 
with once-daily administration. The vasodilatation can induce 
flushing, headache, and ankle edema. 
Experimental data indicate that amlodipine has the potential 
to produce an antiatherosclerotic effect in humans, in part due 
to antioxidant effect or its endothelin antagonistic properties. 
Amlodipine can improve endothelium dysfunction, thanks to 
reduction of calcium influx, and, by its R-enantiomer, facilitate 
the action of nitric oxide or its production. In kidney transplant 
patients, amlodipine can also increase the glomerular filtration 
rate and renal blood flow, and decrease plasma uric acid 
concentration (Chanard et al. 2003).
Valsartan
Valsartan is a specific blocker of the binding of angiotensin II 
to the AT1 receptor, blocking the vasoconstrictor effect and the 
adrenal aldosterone secretion induced by this peptide. Valsartan 
does not significantly increase bradykinin concentrations, in 
contrast to ACE inhibitors. It reduces BP without increasing 
the heart rate. It has a 24-hour effect on BP control due to 
blockade of the AT1 receptor, but there may be an increase 
in angiotensin II concentration acting on AT2 receptors, 
with consequent vasodilatation. In the kidneys, especially at 
the renal tubular level, the stimulation of AT2 could mediate 
natriuresis which could also contribute to the antihypertensive 
effect (Padia et al. 2006 ; Franco et al. 2008). Stopping valsartan 
intake is not associated with rebound of the BP level. 
Pharmacokinetic profile
Limited data are available on the pharmacokinetic properties 
of fixed-dose combinations of amlodipine/valsartan. No drug 
interaction studies have been conducted with fixed-dose 
combinations and other drugs.
Amlodipine
When orally absorbed, peak plasma concentrations of amlodipine 
are reached in 6–8 hours and its bioavailability is 64–80%. It 
has an inherently long half-life of between 30 and 50 hours with 
gradual onset of action and a prolonged effect, which is useful 
for once-daily dosing, and no rebound of HTN when the drug 
is abruptly stopped. It has 98% plasma protein binding and 
is extensively metabolized in the liver to inactive metabolites 
(EMEA 2007; Plosker & Robinson 2008).
Amlodipine can interfere with the metabolism of some drugs 
through the enzyme CYP3A, because this enzyme constitutes the 
pathway of its catabolism. Any substance that induces or inhibits 
CYP3A could affect amlodipine concentration, and amlodipine 
could also modify the concentration of the coadministered drug 
(Wilkinson 2005). An increase in cyclosporin concentrations may 
occur but is of limited clinical significance.
Valsartan
Peak plasma concentrations of valsartan are reached 3 hours 
after oral administration. Its bioavailability is 23% and this is not 
influenced by food. Its half-life is 6 hours and its plasma protein 
binding is over 95%. Like amlodipine, it is metabolized by the 
liver. Valsartan is eliminated mainly as unchanged drug in the 
faeces (83% of the dose) and urine (13% of a dose). It is not 
metabolized by the CYP system and thus has little interference 
with other drugs. In hepatic failure its concentration is increased. 
In renal impairment, its dosage does not need modification and 
it is not removed by dialysis. Its main contraindication is 
pregnancy, because antagonists of the RAAS may be teratogens. 
Valsartan can worsen kidney function in patients with bilateral 
renal artery stenosis, and in this condition of use requires 
surveillance of serum potassium and creatinine (EMEA 2007; 
Plosker & Robinson 2008).
Clinical evidence with amlodipine 
The long-acting third-generation dihydropyridine calcium 
antagonist amlodipine is one of the most commonly used 
antihypertensive agents, and is approved for the treatment 
of HTN and angina at doses from 2.5 to 10 mg/day. It has 
no effects on lipids or insulin sensitivity, but it can increase 
plasma norepinephrine levels. It has been shown to activate 
the sympathetic system during the day and to decrease the 
parasympathetic activity during the night (Karas 2005).
Amlodipine has been studied in patients with coronary artery disease 
and shows benefit compared with placebo or enalapril in terms of 
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cardiovascular events, with a trend towards an antiatherosclerotic 
effect even in normotensive patients who have coronary heart 
disease (Nissen et al. 2004). It may exert a preferential effect in 
lowering central aortic pressures (CAFE Investigators 2006).
Amlodipine is not recommended as first-line treatment in 
hypertensives with proteinuric renal disease because it may 
aggravate proteinuria (Nathan et al. 2005; Bakris et al. 2008). 
It is possible that this is related to an increase in glomerular 
capillary pressure that may occur in patients taking amlodipine 
(Delles et al. 2004). Compared with RAAS blockers, amlodipine 
use in proteinuric kidney disease was not as useful in 
preventing renal disease progression (Agodoa et al. 2001; Lewis 
et al. 2001).
Clinical evidence with valsartan 
Valsartan is an ARB that has been marketed for HTN since 1996. 
It is available in the US at 80–320 mg/day and in Europe at 
80–160 mg/day. Valsartan is approved for the treatment of HTN, 
for congestive heart failure, and also for postmyocardial infarction 
patients in some countries. 
Valsartan has also been described as having antiinflammatory 
properties reducing the high sensitivity C-reactive protein 
level, as shown in the Val-MARC trial. However, this 
antiinflammatory effect has not been confirmed in the VIVALDI 
study comparing valsartan with telmisartan (Ridker et al. 2006; 
Galle et al. 2008).
Comparisons of amlodipine and valsartan
Although not the focus of this review, some comparisons of 
amlodipine and valsartan are relevant to the discussion of the 
combination of both drugs.
Wogen et al. (2003) compared patient adherence with amlodipine, 
lisinopril, or valsartan therapy in people treated for HTN. In a 
usual-care setting, patients receiving valsartan rather than 
lisinopril or amlodipine appear to be more compliant with 
treatment, due to less subjective side effects. Moreover, Elliott 
et al. (2007) reported that, probably for the same reasons, 
the risk of discontinuation of four antihypertensive drugs 
(hydrochlorothiazide, amlodipine, lisinopril, and valsartan) was 
different. The lowest risk of discontinuation was seen with the 
ARB, followed by the ACE inhibitor, then the CCB, with the highest 
discontinuation rate being noted with the thiazide. This could be 
explained by a superior  tolerance profile of ARB compared with 
the other antihypertensive classes.
For cardiovascular protection, an action on oxidative stress 
may be beneficial. Dihydropyridine CCBs have antioxidant 
and antiinflammatory effects that may be independent of their 
BP-lowering action and that yield synergistic vasoprotective 
activity with RAAS blockers (Mason et al. 2003). The reduction 
of oxidative stress and plasma methyl arginine, an endogenous 
inhibitor of nitric oxide synthase, has also been noted in 
patients with chronic renal failure treated with either amlodipine 
or valsartan (Aslam et al. 2006). However, valsartan seems to 
be more effective than amlodipine in restoring endothelial 
function and decreasing oxidative stress in essential HTN 
(Hirooka et al. 2008). 
Clinical evidence with amlodipine/valsartan 
combination
Exforge is a fixed-dose combination of amlodipine, as the 
besilate salt, and valsartan, in the form of film-coated tablets. 
Fixed-dose combinations of amlodipine (5 or 10 mg) and valsartan 
(160 or 320 mg) have been available in the US and several countries 
in Europe since September 2007 for once-daily oral administration 
in patients with HTN who have not had an adequate response 
to amlodipine (or another dihydropyridine CCB) or valsartan 
(or another ARB alone) as monotherapy. Exforge was recently 
approved by the FDA as initial or first-line therapy in patients likely 
to need multiple drugs to achieve their BP goals.
There have been only a few studies testing this combination of 
the two drugs. The addition of valsartan 80 mg/day to amlodipine 
5 mg/day in patients not controlled with amlodipine 5 mg alone 
has been shown to improve exercise performance assessed 
by measurements of cardiac output and total peripheral 
resistance at rest and at peak exercise (Maeda et al. 2006). As 
noted above, in hypertensives not controlled with valsartan as 
monotherapy, a combination of amlodipine and valsartan has 
been shown to be well-tolerated, safe, and effective (Stergiou et 
al. 2005). Combination amlodipine/valsartan was very effective 
in lowering BP in patients in whom monotherapy with various 
other antihypertensives was incompletely effective (Allemann et 
al. 2008). In this study, a variety of drugs were used at baseline as 
monotherapy before the use of amlodipine/valsartan. Poldermans 
et al. (2007) showed that amlodipine/valsartan combination 
therapy was as effective in patients with stage II hypertension as 
lisinopril/hydrochlorothiazide combination therapy.
While several trials have been designed to test the antihypertensive 
efficacy of this combination, very few studies have been devoted 
to analyze its potential benefit in terms of cardiovascular or renal 
protection. The particular case of atrial fibrillation was tested 
by Fogari et al. (2008), who showed that amlodipine/valsartan 
combination therapy was better than atenolol/amlodipine in 
preventing recurrent atrial fibrillation in hypertensive diabetics, 
although comparisons with an ACE inhibitor and a CCB or 
a diuretic would be more appropriate comparators in this 
patient population.
Currently, no information on albuminuria is available for the 
amlodipine/valsartan combination. Nonetheless, Fogari et al. 
(2007a) showed that the amlodipine/telmisartan combination 
has been very useful in decreasing urinary albumin excretion 
in hypertensive diabetic patients with microalbuminuria. The 
clinical development program for amlodipine/valsartan fixed 
combination products has included bioequivalence studies and 
phase III clinical efficacy/safety studies, including placebo- and 
active-controlled studies to justify proposed dosages. All of these 
studies showed efficacy in all grades of HTN, as well as efficacy 
in nonresponders to monotherapy or to previous combination 
therapy (Table 2).
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To date, some clinical trials with combinations of both drugs 
have been published, with a focus on BP control but without 
using home or ABPM, and only one study has been published 
on systolic HTN (Destro et al. 2008). Several studies have 
shown the efficacy of each component drug in reducing BP and 
cardiovascular events, as reviewed above.
Published randomized studies 
1.  Combination therapy with amlodipine/valsartan has been 
compared with that of amlodipine or valsartan monotherapy 
in two large randomized double-blind, placebo-controlled 
studies and their subgroup analyses (Philipp et al. 2007; 
Smith et al. 2007). These studies included 3161 patients with 
mild-to-moderate HTN. The primary efficacy endpoint was the 
change from baseline in mean sitting diastolic (D) BP at the 
end of the 8-week study period. Secondary endpoints were the 
percentage of patients achieving a DBP <90 mmHg or a >10 
reduction from baseline, and change of mean systolic (S) BP.
 The efficacy of the combination was better than either 
monotherapy at the same dose. More than 80% of patients 
treated with amlodipine/valsartan 5/80 mg, 5/160 mg, or 
5/320 mg met the criteria for response. This was also the case 
when the amlodipine dose in the combination was 10 mg.
The same group (Philipp et al. 2007) showed that ~50% of 
the patients treated with the combination of amlodipine 
10 mg and valsartan 320 mg achieved the BP goal of 
<140/90 mmHg at 2 weeks. The combination therapy was 
associated with greater reductions in BP than each separate 
monotherapy or placebo across all patient subgroups, including 
those aged >65 years, black patients, and those with stage II HTN 
(Smith et al. 2007). 
2.  A large, randomized, double-blind, phase IIIb–IV trial in almost 
900 patients evaluated a direct switch to amlodipine/valsartan 
5/160 mg or 10/160 mg once daily in patients whose BP 
was previously uncontrolled by monotherapy with various 
antihypertensive agents (Allemann et al. 2008). Patients 
whose BP was uncontrolled with the combination after 
8–12 weeks could receive diuretics. BP control was achieved 
in 76% and 71% of patients after 8 weeks of combination with 
amlodipine/valsartan 10/160 mg or 5/160 mg, respectively. For 
both dosage regimens, the magnitude of SBP reductions was 
similar regardless of the class of antihypertensive drug used 
prior to randomization.
3.  Brachmann et al. (2008) recently showed that the addition 
of an ARB to CCB-based antihypertensive therapy may 
be associated with enhanced efficacy and reduced risk of 
adverse events. In this 8-week, open-label, single-arm trial, the 
efficacy and tolerability of the combination of amlodipine and 
valsartan was evaluated in patients not responding adequately 
to treatment with amlodipine or felodipine alone. Patients 
aged ≥18 years with moderate essential hypertension (defined 
as mean sitting SBP ≥160 and <180 mmHg) were treated for 
4 weeks with amlodipine 5 mg or felodipine 5 mg once daily. 
At week 4, patients not adequately responding were treated 
for an additional 4 weeks with a fixed dose combination of 
once-daily amlodipine/valsartan 5/160 mg. Of 214 patients 
treated for 4 weeks with amlodipine 5 mg or felodipine 5 mg, 
Trial Design Treatment Patients
Efficacy  
(Philipp et al. 2007; Smith et al. 2007) 
EMEA study 2201 + 2307
Multicenter, double-blind, randomized, 
placebo-controlled, parallel group
8 weeks of amlodipine 2.5, 5 mg; 
valsartan 40, 80, 160, and 320 mg, all 
possible combinations and placebo
1911 patients with mild-to-moderate 
diastolic HTN
Efficacy  
(Philipp et al. 2007; Smith et al. 2007) 
EMEA study 2201 + 2307
Multicenter, double-blind, randomized, 
active-controlled, parallel group
8 weeks of amlodipine/valsartan 
(5/160 mg and 10/160 mg) compared 
with valsartan 160 mg
1250 patients with mild-to-moderate 
diastolic HTN
Efficacy and safety in severe HTN 
(Poldermans et al. 2007) EMEA study 
2308 
Multicenter, double-blind, randomized, 
active-controlled, parallel group
8 weeks of amlodipine/valsartan 
(5/160 mg and 10/160 mg) compared 
with valsartan 160 mg
947 adults with mild-to-moderate HTN 
uncontrolled by valsartan 160 mg
Efficacy and safety EX-FAST  
(Alleman et al. 2008) EMEA study 2401 
mild-to-moderate HTN
Multicenter, double-blind, randomized, 
active-controlled, parallel group
16 weeks of amlodipine 5 or 10 mg/
valsartan 160 mg compared with 
previous monotherapy
894 patients receiving the combination 
(443 with amlodipine 5 mg and 451 
with amlodipine 10 mg) with mild-
to-moderate HTN uncontrolled by 
monotherapy
Efficacy and safety EX-EFFeCTS study 
(Destro et al. 2008) EMEA study 2403
Multicenter, double-blind, randomized, 
active-controlled, parallel group
8 weeks amlodipine/valsartan vs 
amlodipine monotherapy in systolic 
stage II HTN
646 patients with stage II and III HTN 
receiving either the amlodipine 5 or 
10 mg/valsartan 160 mg combination 
(n=322) or amlodipine monotherapy 5 
or 10 mg (n=324)
Nonresponder study ExPress-C trial 
(Trenkwalder et al. 2007)
Open-label, simple arm 5 weeks amlodipine/valsartan  
10/160 mg compared with ramipril  
5 mg/felodipine 5 mg
105 patients with stage II HTN 
uncontrolled by ramipril/felodipine 
after 5 weeks
Nonresponder study  
(Brachmann et al. 2008)  
EXPRESS-M trial
Open-label, simple arm 8 weeks amlodipine/valsartan 
compared with amlodipine or 
felodipine monotherapy
181 patients stage II HTN uncontrolled 
by CCB monotherapy
CCB, calcium channel blocker; EMEA, European Medicines Agency; HTN, hypertension.
   Table 2 | Randomized trials with amlodipine/valsartan combination in hypertension
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181 failed to achieve mean sitting SBP <140 mmHg. These 
181 nonresponders were treated for an additional 4 weeks with 
amlodipine/valsartan 5/160 mg: over half of them achieved 
target BP level (<140/90 mmHg).
4.  Poldermans et al. (2007) showed that better BP control 
was achieved with the combination of amlodipine/valsartan 
5/160 mg or 10/160 mg than with the combination of lisinopril 
10 or 20 mg and hydrochlorothiazide 12.5 or 25 mg in adult 
patients with stage II HTN. Mean sitting SBP/DBP was reduced 
by 36/29 mmHg and 32/28 mmHg, respectively, but this was 
not statistically significant. Subgroup analyses showed that 
both combination regimens reduced BP from baseline in two 
important patient groups; those aged >65 years at baseline and 
those with SBP >180 mmHg at baseline (i.e. stage III HTN).
5.  Trenkwalder et al. (2007) tested the efficacy of treatment 
with the combination of ramipril 5 mg and felodipine 5 mg. 
In patients who were resistant to this combination, they 
evaluated the efficacy of switching to amlodipine/valsartan 
10/160 mg. The amlodipine/valsartan combination led to a 
significant additional BP reduction, of 15 mmHg for SBP and 
7 mmHg for DBP (P<0.001). Moreover, there was a better safety 
and tolerability profile for amlodipine/valsartan compared with 
ramipril/felodipine.
6.  Destro et al. (2008) assessed the efficacy and safety of 
amlodipine/valsartan versus amlodipine monotherapy in 
patients with systolic stages II and III HTN (sitting SBP 
between 160 and 200 mmHg) in a randomized, double-blind, 
8-week trial. A total of 646 patients were enrolled, of whom 
322 were treated with amlodipine/valsartan 5/160 mg (group 1) 
and 324 were treated with amlodipine 5 mg for 2 weeks 
(group 2). For the remainder of the study, there was a dose 
increase to 10/160 mg in group 1 and 10 mg in group 2. At 
week 4, if patients were not controlled (SBP <130 mmHg), 
open label hydrochlorothiazide 12.5 mg could be added.
At week 4, the change from baseline SBP was significantly 
greater with amlodipine/valsartan compared with amlodipine 
monotherapy (decrease in SBP of 30 mmHg versus 24 mmHg; 
P<0.0001). By the end of the study, SBP was reduced from a 
baseline of 171 to 137 mmHg in the amlodipine/valsartan arm 
compared with 145 mmHg in the amlodipine treatment arm 
(P<0.0001). The difference in response was similar whatever 
the subgroup analysis (i.e. the elderly, those with severe HTN, 
obese patients, or those with diabetes mellitus).
Tolerability and safety
The most frequently reported adverse events with amlodipine/
valsartan were ankle edema, headache, nasopharyngitis, upper 
respiratory tract infection, and dizziness. The aggregate frequency 
of adverse events was not different for amlodipine monotherapy 
(46%) as compared with amlodipine/valsartan combination 
(44%) but was higher than that reported for valsartan alone 
(40%) (Philipp et al. 2007). The frequency of ankle edema was 
greatest with amlodipine alone (9%), followed by the combination 
(5%), and was least common with valsartan monotherapy 
(2%). For the placebo group, the frequency of edema was 3% 
(Philipp et al. 2007).
Ankle edema was studied in detail by Fogari et al. (2007b). Objective 
ankle foot volume and pretibial subcutaneous tissue pressure were 
masked endpoints after 6 weeks of amlodipine monotherapy or 
amlodipine/valsartan combination therapy. Ankle edema was most 
common in those on amlodipine monotherapy, least common in 
those on valsartan monotherapy, and of intermediate frequency in 
those on combination therapy. The ankle edema with CCB may 
be due to high capillary hydrostatic pressure from precapillary 
vasodilatation. Several drug classes have relevant venodilating 
potential, including ACE inhibitors, ARBs, and nitrates. The use of 
valsartan, which has a mixed vasodilating effect on arteriolar and 
venular sites, may decrease the postcapillary pressure thereby 
normalizing transcapillary pressure and reducing edema. Another 
mechanism explaining a less frequent development of edema with 
the combination of amlodipine and valsartan could be the natriuretic 
effect of angiotensin blockade. 
In the study published by Poldermans et al. (2007), most of the 
adverse events were not considered to be related to the study 
drugs. Mild-to-moderate adverse events were reported in 41% of 
patients treated with amlodipine/valsartan and 32% in the group 
treated with lisinopril/hydrochlorothiazide. Headache (11%) and 
peripheral edema (8%) were reported mainly in the amlodipine/
valsartan group whereas diarrhea and pharyngitis occurred 
mainly in the lisinopril/hydrochlorothiazide group (6% for both). 
Cough occurred in 3% of those on lisinopril, but in fewer than 2% 
of those in the amlodipine/valsartan combination
Economic evidence
In HTN without any other associated cardiovascular risk factor, 
the treatment cost increases as the target for HTN is lowered but 
this effect is attenuated when the population tested is older or has 
higher cardiovascular risk. Cost effectiveness may be better for 
older compared to younger people and for higher starting levels 
of BP. Cost effectiveness of treatment for HTN is also improved 
in secondary prevention or in the presence of diabetes (Jönsson 
et al. 2003). 
The large majority of trials in the treatment of HTN have shown 
that the benefit from the treatment correlates with the decrease in 
BP. Recently some trials have suggested a benefit in addition to 
the BP decrease when using CCB and/or a blocker of the 
RAAS such as was observed in the LIFE or ASCOT trials (Dahlöf 
et al. 2002, 2005). However, the combination of two blockers of 
the RAAS (i.e. ACE inhibitor and ARB) has not demonstrated 
such benefit. In the VALIANT study, the combination of valsartan 
and captopril increased the rate of adverse events (Pfeffer et al. 
2003). Similarly, in the Valsartan Heart Failure Trial (Val-HeFT), 
the combination of valsartan and ACE inhibitors or beta blocker 
was associated with a higher rate of adverse events (Cohn 
& Tognai 2001). In the ONTARGET trial, the combination of ramipril 
and telmisartan conferred no additional benefit compared with 
monotherapy in high cardiovascular risk populations (Yusuf et 
al. 2008). Considering absolute cost, paying for amlodipine and 
valsartan separately is cheaper, as shown in Table 3. However, the 
problem of compliance is inversely linked to the number of pills 
to be taken, which may cancel that small cost advantage (Osterberg 
& Blaschke 2005).
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Patient group/population
For the amlodipine/valsartan combination, the population who may 
benefit from its use are those patients with stage II or III HTN and 
those who have not sufficiently responded to an antihypertensive 
monotherapy. An additional population of interest is those with 
chronic kidney disease, especially when the estimated GFR is less 
than 60 mL/min/1.73m³.
No specific drug interaction studies have been conducted with 
this combination, but interaction of the individual single agents 
with other drugs exists and should be kept in mind (see above).
In April 2008, the EMEA published information about the avoidance 
of this drug combination throughout pregnancy. Since the fourth 
of December 2007, the FDA has appoved the use of valsartan for 
treating children with HTN, so amlodipine/valsartan could now be 
used in patients under 18 years of age but not in patients allergic 
to amlodipine or other medicines in the dihydropyridine class or 
with allergy to valsartan.
Regarding safety, it should be kept in mind that this combination 
includes a blocker of the action of angiotensin II. Thus, in all clinical 
situations such as fever, dehydration, or diarrhea, in which the 
renal blood blow must autoregulate to avoid renal insufficiency, the 
ARB must be stopped and amlodipine alone continued if the 
patient still requires antihypertensive therapy. Potassium and 
creatinine should be monitored in those with moderate renal 
impairment. Moreover, in therapeutic conditions that predispose 
to hyperkalemia (e.g. use of NSAIDs, spironolactone, or ACE 
inhibitors, as well as acute or chronic renal insufficiency), the 
presence of the ARB valsartan could mean that the combination 
may need to be stopped. Caution is advised when prescribing 
fixed-dose amlodipine/valsartan to patients with hepatic 
impairment, or biliary obstruction, or when increasing the dosage 
of the combination in elderly patients. Bilateral renal artery stenosis 
is another contraindication for the use of this combination.
Dosage, administration, and formulation
In the US, Exforge is available as film-coated tablets of amlodipine 
5 and 10 mg and valsartan 160 and 320 mg, to be administered 
once daily, taken with water, with or without food. Although a direct 
switch from monotherapy to the fixed dose may be appropriate 
for some patients, individual dose titration with amlodipine and 
valsartan is generally recommended before changing to a fixed-
dose combination (EMEA 2007).
Clinical value
As reviewed, this combination is effective in terms of reduction 
in BP. HTN is an important risk factor for cardiovascular 
complications and its management still needs improvement. 
The development of new strategies to improve the BP control 
is welcome. The development of efficient and safe combination 
therapy is one of these strategies as many patients with HTN 
need at least two antihypertensive agents to achieve BP control. 
Exforge is a new drug combination associating two well-tested 
antihypertensive products: the CCB amlodipine and the ARB 
valsartan. The amlodipine/valsartan combination is an association 
with potential advantages in cardiovascular protection. 
Clinical trials are ongoing to assess the efficacy and safety of 
this combination, and it is likely that others will follow. Currently 
available data have shown that this new formulation is well 
tolerated and effective even in severe HTN. Its cost, however, 
remains high compared with the individual component drugs and 
economic studies quantifying the possible benefit associated 
with improved compliance would be welcome.
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